Jérusalem

Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting

Retrieved on: 
Monday, August 2, 2021
Musculoskeletal system, Organ systems, Anatomy, Osteopathies, Skeletal system, Aging-associated diseases, Endocrine diseases, Rheumatology, Osteoporosis, Bone density, Bone, Entera

BOSTON and JERUSALEM, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its poster presentation titled “A Six-month Phase 2 Study of Oral PTH in Postmenopausal Women with Low Bone Mass - An Interim Three-Month Analysis” has been selected by the Program Committee of the American Society for Bone and Mineral Research (ASBMR) for its Annual Meeting scheduled to take place on October 1-4, 2021 in San Diego, California. Dr. Arthur Santora, Entera’s Chief Medical Officer, will present the poster at both the plenary session on October 1 and the general session on October 2, as well as a special session on the Biology of the Aging Skeleton Symposium on September 30.

Key Points: 
  • Three and 6 month results, previously reported by Entera in June 2021 can be found here .
  • Osteoporosis, characterized by low bone mass and deterioration of bone tissue, can lead to decreased bone strength and increased risk of fracture.
  • The Companys most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

BrainsWay to Report Second Quarter 2021 Financial Results on August 11, 2021

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Neuroscience, Neurotechnology, Medicine, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Brainsway, Transcranial magnetic stimulation, Neurostimulation, TMS

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

Key Points: 
  • BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.
  • BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
  • Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS.

MindPath Care Centers Hosts Open House in Charlotte to Introduce FDA-Cleared Deep TMS™ Treatment for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Psychiatry, Neuroscience, Neurotechnology, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Transcranial magnetic stimulation, Brainsway, Major depressive disorder, Obsessive–compulsive disorder

The event will feature an opportunity for local mental health providers in the Charlotte area to meet the MindPath Care Center staff and watch live demonstrations of BrainsWays Deep Transcranial Magnetic Stimulation (Deep TMS) treatment offerings for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).

Key Points: 
  • The event will feature an opportunity for local mental health providers in the Charlotte area to meet the MindPath Care Center staff and watch live demonstrations of BrainsWays Deep Transcranial Magnetic Stimulation (Deep TMS) treatment offerings for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).
  • Because Deep TMS penetrates deeper and broader in the brain than traditional TMS, there is evidence that response rates are higher than traditional TMS.
  • For more information regarding Deep TMS services at MindPath Care Centers, visit www.mindpathcare.com/TMS or call the clinic at 877-876-3783.
  • Community Psychiatry and MindPath Care Centers have combined to expand patient access to high-quality, evidence-based, outpatient mental health care across the United States.

BrainsWay to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Retrieved on: 
Tuesday, July 6, 2021
Branches of biology, Neuroscience, Neurotechnology, Medicine, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Brainsway, Transcranial magnetic stimulation, Neurostimulation, TMS

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

Key Points: 
  • BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.
  • BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
  • Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS.

Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis

Retrieved on: 
Monday, June 28, 2021
Hormones, Branches of biology, Endocrine system, Glands, Parathyroid gland, Osteoporosis, Parathyroid hormone

EB613 is an oral formulation of human parathyroid hormone (1-34), or PTH, and is positioned to be the first oral bone building (anabolic) product to treat osteoporosis patients.

Key Points: 
  • EB613 is an oral formulation of human parathyroid hormone (1-34), or PTH, and is positioned to be the first oral bone building (anabolic) product to treat osteoporosis patients.
  • Dr. Tripto-Shkolnik will provide context on the results of the study and the benefits of an oral drug to treat osteoporosis.
  • The conference call will take place on Wednesday, June 30, 2021 from 12-1pm EDT and will include a question-and-answer session.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints

Retrieved on: 
Wednesday, June 23, 2021
Clinical endpoint, Clinical research

The most important BMD endpoint change in lumbar spine (LS) BMD after 6 months was met.

Key Points: 
  • The most important BMD endpoint change in lumbar spine (LS) BMD after 6 months was met.
  • An increase in LS BMD is the primary endpoint for the 505(b)(2) pathway as was described by the FDA in Enteras pre-IND meeting.
  • In the current study LS BMD increased 3.78% (p
  • Furthermore, EB613 had a significant impact on both femoral neck and total hip BMD at 6 months.

Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union

Retrieved on: 
Thursday, June 17, 2021
Hormones, Endocrine system, Monopoly, Patent, Parathyroid hormone, Unitary patent

The patent addresses Enteras oral PTH formulations currently in advanced clinical stages for osteoporosis and hypoparathyroidism.

Key Points: 
  • The patent addresses Enteras oral PTH formulations currently in advanced clinical stages for osteoporosis and hypoparathyroidism.
  • This is a critical patent that covers lead PTH products utilizing Enteras platform technology.
  • This European Union patent, along with a variety of other patents covering oral formulations and target indications, granted and pending, provide Entera with robust protection of its intellectual property.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

BrainsWay to Present at the Raymond James Human Health Innovation Conference

Retrieved on: 
Tuesday, June 8, 2021
Branches of biology, Neuroscience, Neurotechnology, Medicine, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Brainsway, Transcranial magnetic stimulation, Neurostimulation, TMS

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

Key Points: 
  • BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.
  • BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
  • Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS.

BrainsWay to Present at Clinical TMS Society Annual Meeting and Psych Congress Elevate

Retrieved on: 
Monday, June 7, 2021
Branches of biology, Neuroscience, Neurotechnology, Medicine, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Brainsway, Transcranial magnetic stimulation, Neurostimulation, Tel Aviv Stock Exchange

(NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments of mental health disorders, today announced the Company will participate in the upcoming global medical conferences:

Key Points: 
  • (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments of mental health disorders, today announced the Company will participate in the upcoming global medical conferences:
    Clinical TMS Society Annual Meeting from June 10-12.
  • The Annual Meeting of the Clinical TMS Society provides a unique opportunity to connect with TMS providers and researchers from around the world.
  • Additionally, the Company will be hosting two showcase presentations featuring novel research and the clinical utility of Deep TMS.
  • Psych Congress Elevate: Virtual Experience from June 11- 13.

BrainsWay Announces Positive OCD Coverage Policy by Blue Cross Blue Shield® Licensee HCSC

Retrieved on: 
Wednesday, June 2, 2021
Health maintenance organizations, Branches of biology, Health Care Service Corporation, Insurance companies, Illinois, Blue Cross Blue Shield Association, BCBS, Types of insurance, Health insurance, Brainsway

HCSC, an independent licensee of Blue Cross Blue Shield Association, is the largest customer-owned health insurance company, and fourth largest overall, in the U.S., covering approximately 17 million members.

Key Points: 
  • HCSC, an independent licensee of Blue Cross Blue Shield Association, is the largest customer-owned health insurance company, and fourth largest overall, in the U.S., covering approximately 17 million members.
  • HCSC offers a wide variety of health and life insurance products and related services through its operating divisions and subsidiaries, including Blue Cross and Blue Shield (BCBS) of Illinois, Montana, New Mexico, Oklahoma, and Texas.
  • We are thrilled to have received our first BCBS coverage policy for OCD from HCSC, one of the largest health insurers in the U.S., said Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay.
  • We will continue our work to drive further positive coverage developments in this important indication from additional BCBS systems and other major health plans.